Abbvie Inc ABBV

$294.89 +4.10 (1.41%)

Valuation

Market cap
521,009,600,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
26.75
P/E (forward)
20.89
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
6,898,100
Avg volume
4,609,686
Day's range
$291.01 – $298.74
Shares out
1,766,793,000
Stochastic %K
81%
Beta
0.24
Analysts
Moderate Buy
Price target
$283.87

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

GlobalTradersAcademy Nov 1, 9:25 PM
$7.0M of options premium hit $ABBV, mostly calls. “Options traders are leaning upside on AbbVie after the jump in attention, with most of today's premium in calls. It's up about 3% from a week ago, at its highest level in a month. $SPY $QQQ Inside the article: the biggest contracts behind the flow and where the money is leaning. Anyone else watching this flow on $ABBV? Full story: https://globaltradersacademy.com/articles/abbvie-abbv-options-flow-7-0m-in-premium-82-in-calls-as-the-stock-trends-2?utm_source=stocktwits&utm_medium=social Free 14-day trial: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=ABBV&tool=options
1 replies
55X_ROI_Q1_2026 Nov 1, 8:28 PM
$SLS Onureg / Oral Az is the BAT for AML CR1 24.7 months • adding Venetoclax to Onureg Failed to increase survival in 5 Clinical trials - including Failing 2 Large Phase 3’s conducted by $ABBV for AML Remission Maintenance. • Gps Phase MOS in the same exact Setting was > 67.6 months BAT 24 - Gps 67 it is not complicated $SLS is the next $MRNA
0 replies
Zakily Nov 1, 8:25 PM
$ABBV may the democrat sweep short this stock to hell
0 replies
cert Nov 1, 6:42 PM
$PBYI $IOVA $ABBV $AMGN
0 replies
Maribor Nov 1, 5:16 PM
$ABBV https://www.latimes.com/california/story/2026-10-31/california-botox-doctor-bilked-45-million-from-medicare-feds-say
1 replies
MarketKingdoms Nov 1, 11:46 AM
$ABBV posted Q3 '26 revenue of $17.4B (+10% YoY), beating estimates by $200M, with adj. EPS of $3.82. Skyrizi sales hit $5.8B (+22.9%) and Rinvoq $2.7B (+24.3%). Neuroscience grew 19.5%; nine products posted double-digit growth. FY26 revenue outlook raised $200M, the third increase this year; dividend +5.2%. FY26 EPS guided at $13.95–13.99. Catalysts in play - Skyrizi Crohn's subQ induction launch supports 2027 growth. - Rinvoq US vitiligo and alopecia approvals expected soon. - Intentamig multiple myeloma FDA approval targeted for 2027. - Epkinly frontline DLBCL submissions planned early 2027. - Juvmo Parkinson's launch ramp; Vyalev tracking >$1B. - Skyrizi captures ~50% of new psoriasis and IBD starts. Risks to watch - Humira sales -30.6% amid biosimilar erosion. - Imbruvica -26.1% on IRA pricing and competition. - Juvéderm -11.8%; aesthetics remains weak. - BoNT/E US approval delayed to mid-2027. - Vraylar faces IRA price setting in 2027. - 340B duplicate discounts and pipeline execution risks.
0 replies
Equireason Oct 31, 8:00 PM
$ABBV Claim going around: "they raised guidance." - Correct vs October 5: adjusted EPS outlook is $13.95–13.99 now vs $13.76–13.96 (Oct 30 call) - Not correct vs where the year began: February's range was $14.37–14.57, so the midpoint is ~3.5% lower - The 2026 path: cut in early April, raised late April, cut in July, trimmed again in July, cut Oct 5, raised Oct 30 - Skyrizi: $5.5B in Q2, ~24% above a year earlier (10-Q) For: the core immunology products keep growing and the range is now 4 cents wide. Against: acquired IPR&D and milestone charges ($0.58/share year-to-date as of July) were part of the cuts and can come back with each new deal.
0 replies
GlobalTradersAcademy Oct 31, 3:50 PM
$7.0M of options premium hit $ABBV, mostly calls. The stock is up about 3% from a week ago, at its highest level in a month. $SPY $QQQ Inside the article: the biggest contracts behind the flow and where the money is leaning. Anyone else watching this flow on $ABBV? Full story: https://globaltradersacademy.com/articles/abbvie-abbv-options-flow-7-0m-in-premium-82-in-calls-as-the-stock-trends?utm_source=stocktwits&utm_medium=social Free 14-day trial: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=ABBV&tool=options
1 replies